This site is intended for Healthcare Professionals outside the US

JAKAVI has a well-characterised safety profile

Safety profile established in clinical study and real-world experience1

JAKAVI safety profile assessed in multiple Polycythemia Vera specific trials

Number of patients shown for the Phase III trial includes patients receiving either JAKAVI or BAT.

One enrolled patient in this trial was not included in the safety analysis.

  • The safety profile of JAKAVI has been well established through clinical use in myelofibrosis as well as in PV1

The estimated cumulative patient exposure to JAKAVI is more than 14,000 patient treatment years1

Next: Safety Profile in RESPONSE

BAT=best available therapy.


  1. Data on file. Novartis Pharma AG. Basel, Switzerland.